References:
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 2021-05-01;71(3):209-49.
2. Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. J Hepatocell Carcinoma. 2021 2021-01-20;8:387-401.
3. Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, et al. Global, regional and national burden of primary liver cancer by subtype. EUR J CANCER. 2022 2022-01-01;161:108-18.
4. Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. GASTROENTEROLOGY. 2019 2019-01-01;156(2):477-91.
5. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019 2019-10-01;16(10):589-604.
6. Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. J Hepatocell Carcinoma. 2022 2022-01-20;9:233-63.
7. Falette PM, Pellat A, Assaf A, Ginestet C, Brezault C, Dhooge M, et al. Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review. Cancers (Basel). 2022 2022-05-10;14(10).
8. Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J HEMATOL ONCOL. 2019 2019-03-12;12(1):27.
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 2008-07-24;359(4):378-90.
10. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. LANCET ONCOL. 2009 2009-01-01;10(1):25-34.
11. Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014 2014-01-20;2014:638747.
12. Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018 2018-06-01;7(6):2641-53.
13. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. LANCET. 2018 2018-03-24;391(10126):1163-73.
14. Sherman M. Regorafenib for treatment of hepatocellular carcinoma. HEPATOLOGY. 2018 2018-03-01;67(3):1162-5.
15. Galle PR, Dufour JF, Peck-Radosavljevic M, Trojan J, Vogel A. Systemic therapy of advanced hepatocellular carcinoma. FUTURE ONCOL. 2021 2021-04-01;17(10):1237-51.
16. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. LANCET. 2017 2017-01-07;389(10064):56-66.
17. Tumen D, Heumann P, Gulow K, Demirci CN, Cosma LS, Muller M, et al. Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. Biomedicines. 2022 2022-12-09;10(12).
18. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018 2018-07-05;379(1):54-63.
19. Justice CN, Derbala MH, Baich TM, Kempton AN, Guo AS, Ho TH, et al. The Impact of Pazopanib on the Cardiovascular System. J Cardiovasc Pharmacol Ther. 2018 2018-09-01;23(5):387-98.
20. Dobbin S, Petrie MC, Myles RC, Touyz RM, Lang NN. Cardiotoxic effects of angiogenesis inhibitors. Clin Sci (Lond). 2021 2021-01-15;135(1):71-100.
21. Pinkhas D, Ho T, Smith S. Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development. Cardiooncology. 2017 2017-01-20;3.
22. Fan Q, Hu Y, Yang C, Zhao B. Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data. INT IMMUNOPHARMACOL. 2019 2019-11-01;76:105866.
23. Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. INT J MED SCI. 2013 2013-01-20;10(7):796-803.
24. Moslehi JJ. Cardiovascular Toxic Effects of Targeted Cancer Therapies. N Engl J Med. 2016 2016-10-13;375(15):1457-67.
25. Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors. J AM COLL CARDIOL. 2015 2015-09-08;66(10):1160-78.
26. Rimassa L, Danesi R, Pressiani T, Merle P. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. CANCER TREAT REV. 2019 2019-07-01;77:20-8.
27. Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, et al. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). CANCER-AM CANCER SOC. 2018 2018-06-01;124(11):2365-72.
28. Yuan X, Mitsis A, Nienaber CA. Current Understanding of Aortic Dissection. Life (Basel). 2022 2022-10-14;12(10).
29. Tsuchiya A, Ogawa M, Watanabe Y, Kimura N, Hayashi K, Suda T, et al. Successful treatment of aortic dissection during sorafenib therapy for hepatocellular carcinoma. Clin Case Rep. 2018 2018-08-01;6(8):1643-4.
30. Takada M, Yasui T, Oka T, Shioyama W, Kuroda T, Nakai Y, et al. Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma. INT HEART J. 2018 2018-09-26;59(5):1174-9.
31. Oshima Y, Tanimoto T, Yuji K, Tojo A. Association Between Aortic Dissection and Systemic Exposure of Vascular Endothelial Growth Factor Pathway Inhibitors in the Japanese Adverse Drug Event Report Database. CIRCULATION. 2017 2017-02-21;135(8):815-7.
32. Zhou Z, Cecchi AC, Prakash SK, Milewicz DM. Risk Factors for Thoracic Aortic Dissection. Genes (Basel). 2022 2022-10-07;13(10).
33. Dorks M, Jobski K, Herget-Rosenthal S, Hoffmann F, Douros A. Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection-A pharmacovigilance analysis. Pharmacol Res Perspect. 2021 2021-02-01;9(1):e707.
34. Hatem R, Bebawi E, Schampaert E. Potential Sunitinib-Induced Coronary Artery and Aortic Dissections. CAN J CARDIOL. 2017 2017-06-01;33(6):817-30.
35. Niwa N, Nishiyama T, Ozu C, Yagi Y, Saito S. Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib. ACTA ONCOL. 2015 2015-04-01;54(4):561-2.
36. Bonnet C, Sibon I. Potential role of anti-VEGF targeted therapies in cervical artery dissection: A case report. Rev Neurol (Paris). 2015 2015-09-01;171(8-9):677-9.
37. Bronte G, Bronte E, Novo G, Pernice G, Lo VF, Musso E, et al. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. EXPERT OPIN DRUG SAF. 2015 2015-02-01;14(2):253-67.
38. Chintalgattu V, Ai D, Langley RR, Zhang J, Bankson JA, Shih TL, et al. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J CLIN INVEST. 2010 2010-02-01;120(2):472-84.
39. Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. 2018 2018-01-20;2:13.
40. Scott SS, Greenlee AN, Matzko A, Stein M, Naughton MT, Zaramo TZ, et al. Intracellular Signaling Pathways Mediating Tyrosine Kinase Inhibitor Cardiotoxicity. HEART FAIL CLIN. 2022 2022-07-01;18(3):425-42.
41. Kivela R, Hemanthakumar KA, Vaparanta K, Robciuc M, Izumiya Y, Kidoya H, et al. Endothelial Cells Regulate Physiological Cardiomyocyte Growth via VEGFR2-Mediated Paracrine Signaling. CIRCULATION. 2019 2019-05-28;139(22):2570-84.
42. Takagi K, Takai M, Kawata K, Horie K, Kikuchi M, Kato T, et al. [Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report]. Hinyokika Kiyo. 2015 2015-09-01;61(9):347-51.
43. Paschke L, Lincke T, Muhlberg K, Lindner TH, Paschke R. Myocardial Infarction after Long-Term Treatment with a Tyrosine Kinase Inhibitor (TKI) with Anti-VEGF Receptor Activity. Case Rep Endocrinol. 2019 2019-01-20;2019:7927450.
44. Duran JM, Makarewich CA, Trappanese D, Gross P, Husain S, Dunn J, et al. Sorafenib cardiotoxicity increases mortality after myocardial infarction. CIRC RES. 2014 2014-05-23;114(11):1700-12.
45. Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, et al. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2012 2012-03-01;69(3):773-80.
46. Lu Z, Wu CY, Jiang YP, Ballou LM, Clausen C, Cohen IS, et al. Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. SCI TRANSL MED. 2012 2012-04-25;4(131):131r-150r.